A facility billing AED 40 million at a four percent margin has not lost the points to medicine, it has lost them to operations.

A facility billing AED 40M in a year and keeping four percent of it has an EBITDA problem that has nothing to do with its doctors. The clinical work is sound, the patients arrive, the top line is real. Yet against a sector benchmark of 12 to 18 percent, that operation is leaving somewhere between AED 3M and AED 5M on the table every year, and it has been doing so quietly for long enough that the low number now feels normal. Owners tend to reach for the two easy explanations first. Volume is too low, or prices are too soft. Both are usually wrong. Volume of AED 40M is not the constraint, and a broad price rise in a payer-driven market gets clawed back at the claims desk faster than it lands. The points did not vanish. They leaked, in specific places, through specific lines you can name once you look at the operation the right way.

Start from the position that revenue is recorded at the top line and margin is built and lost underneath it. A facility at four percent is not running a bad clinical model. It is running a good clinical model on operating infrastructure that was never engineered for margin. The costing is coarse, so no one knows the true contribution of a given procedure and pricing is guesswork. Procurement is fragmented across suppliers with no leverage applied to the spend. The fee schedule was set years ago and never rebuilt against actual cost and payer behaviour. Staffing follows habit rather than demand. None of that shows up in a quality audit or a patient survey, and none of it is visible to a clinician doing good work. All of it shows up in the eight to fourteen points sitting between your facility and its benchmark.

The recovery begins with a P&L per service line, because the leak is never spread evenly. It concentrates. Two or three lines are usually carrying loss that the earners quietly absorb, and the group has no idea which is which. Once each line has direct revenue, direct cost, allocated overhead and a contribution margin of its own, the underperformers stop hiding inside the consolidated figure. A day-surgery line that looked profitable at the facility level turns out to lose money once implant cost and theatre time are charged to it honestly. That is not bad news. That is the first line item you can actually act on, and it was invisible the day before. The same exercise also finds the earners you have been underinvesting in, the ones that would return more if you gave them more capacity.

Two levers move the number fastest once the P&L is honest. Pricing redesign rebuilds your schedule around real cost and real payer economics rather than a legacy list, and it holds because it is defensible line by line at the claims desk instead of being a blanket increase that invites denials. Procurement consolidates spend that has been scattered across too many suppliers, converts volume into leverage, and takes cost out of consumables and implants without touching clinical standards. Neither is a one-off cut that reverses the moment attention moves elsewhere. Both become a discipline that keeps working after we leave. On a AED 40M base, moving even part way to benchmark is several million AED a year in recovered EBITDA, and it is recovered from cost and price structure rather than from squeezing the clinical floor or chasing more patients through the door. The two levers reinforce each other. A clean cost base makes the new pricing defensible at the claims desk, and pricing that survives payer scrutiny protects the procurement savings from being competed away over the following year.

The single largest pocket of leaked margin in a surgical facility usually sits in the room nobody in finance owns. Theatre utilisation gets filed with the scheduler or the nurse manager, yet the theatre is the most capital-intensive asset the facility holds, staffed by its most expensive people. A facility running its theatres at 55 percent and one running at 75 percent can post the same revenue and land very different EBITDA, because the second spreads the same fixed cost across far more billable work. The loss arrives at both ends of the day. Late starts and unfilled gaps are the visible half; cases that overrun push staff into overtime and generate the cancellations that become tomorrow's idle time. Neither is a clinical failure. Both trace to how the day was planned. Measure true utilised hours against funded hours and the gap reads as a direct line to recoverable margin.

Labour is the largest line on the P&L and the one built least deliberately. Most facilities roster from a template that has barely changed in years, adjusted at the edges when someone resigns, and never rebuilt around the demand curve. The result is a building that is overstaffed on a quiet Tuesday afternoon and understaffed on a Monday surge, paying for the average and living with the worst of both. The idle cost and the agency and overtime spend that plugs the peaks land together on the same statement. Demand moves by hour, day, season and service line in patterns stable enough to plan against, so shaping the roster to the arrival curve takes cost out and improves coverage at once. It is not a headcount cut. The constraints are hard: DHA and DoH ratio and skill-mix floors must hold at every hour, not on a comfortable daily average, and a clinician who is not credentialed cannot bill however well the shift is planned.